Castle Biosciences had its Relative Strength (RS) Rating upgraded from 67 to 77 Wednesday — a welcome improvement, but still short of the 80 or better score you look for.
This exclusive rating from Investor's Business Daily identifies share price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners often have an RS Rating of at least 80 as they begin their biggest runs. See if Castle Biosciences can continue to show renewed price strength and hit that benchmark.
Can You Really Time The Stock Market?
Castle Biosciences has moved more than 5% past a 25.91 entry in a first-stage consolidation, meaning it's now out of a proper buy zone. Look for the stock to offer a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week line.
The company showed 0% earnings growth in its most recent report. Sales increased 40%.
Castle Biosciences holds the No. 9 rank among its peers in the Medical-Services industry group. Hims & Hers Health, Guardant Health and Option Care Health are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
